Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211228 | 0.81 | FDPS (0.37) | AAK1TSHRKDM4EFDPSAKT1 | |
| SCHEMBL25852154 | 0.81 | KMT2A (0.59) | MEN1KMT2AAKT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2061803 | 0.81 | SLC6A4 (0.43) | AAK1MEN1KMT2AFDPSAKT1 | |
| SCHEMBL5002556 | 0.81 | L3MBTL1 (0.40) | AAK1TSHRMEN1KMT2AKDM4E | |
| SCHEMBL30278336 | 0.80 | NPY5R (0.41) | AAK1 | |
| SCHEMBL5002591 | 0.79 | — | — | |
| SCHEMBL3143341 | 0.78 | MEN1 (0.42) | AAK1MEN1KMT2AAKT1ALDH1A1 | |
| SCHEMBL27612638 | 0.78 | CETP (0.41) | AAK1TSHRMEN1KMT2AKDM4E | |
| SCHEMBL28520847 | 0.76 | L3MBTL1 (0.38) | KDM4EFDPSAKT1ALDH1A1HPGD | |
| SCHEMBL8605151 | 0.76 | HDAC3 (0.40) | KDM4EFDPSAKT1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459561-B2 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2008-12-02 | — | — | US | disclosed |
| US-7459561-B2 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2008-12-02 | — | — | US | disclosed |
| US-7189858-B2 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2007-03-13 | — | — | US | disclosed |
| US-7189858-B2 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2007-03-13 | — | — | US | disclosed |
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-7151182-B2 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2006-12-19 | — | — | US | disclosed |
| EP-1280795-B1 | N-SUBSTITUTED CARBAMOYLOXYALKYL-AZOLIUM DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20050038075-A1 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2005-02-17 | — | — | US | disclosed |
| US-20050038038-A1 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2005-02-17 | — | — | US | disclosed |
| US-6812238-B1 | WATER SOLUBLE FUNGICIDES FOR SYSTEMIC MYCOSES; ORAL AND PARENTERAL ADMINISTRATION | BASILEA PHARMACEUTICA AG (CH) | 2004-11-02 | — | — | US | disclosed |
| US-6812238-B1 | WATER SOLUBLE FUNGICIDES FOR SYSTEMIC MYCOSES; ORAL AND PARENTERAL ADMINISTRATION | BASILEA PHARMACEUTICA AG (CH) | 2004-11-02 | — | — | US | disclosed |
| EP-1280795-A2 | N-SUBSTITUTED CARBAMOYLOXYALKYL-AZOLIUM DERIVATIVES | Basilea Pharmaceutica AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001032652-A2 | N-SUBSTITUTED CARBAMOYLOXYALKYL-AZOLIUM DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, NAALAD2 | AAK1 2946/4885TSHR 4298/4885MEN1 458/4885 |
| US-20050038038-A1 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, NAALAD2 | AAK1 2830/4885TSHR 4418/4885MEN1 692/4885 |
| US-20050038075-A1 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, CPS1 | AAK1 2701/4885TSHR 4522/4885MEN1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.